Safety of Co-administering Olanzapine and Benzodiazepines for Acute Agitation

Norepinephrine as the Preferred Vasopressor After Cardiac Arrest

Your patient has a pulse again, but will your vasopressor choice determine whether they keep it? In this episode, we tackle one of the most common yet underappreciated decisions in post-cardiac arrest care: epinephrine or norepinephrine for post-ROSC hypotension. We break down the physiology of the stunned myocardium, explore why epinephrine may increase the risk of recurrent cardiac arrest, and examine the landmark trials and latest meta-analysis that are reshaping clinical practice. Most importantly, we translate the evidence into practical bedside recommendations you can apply on your very next shift. If you care for critically ill patients in the emergency department, ICU, or anywhere along the resuscitation continuum, this is an episode you won't want to miss.

Prolonged Beta-Lactam Infusion Strategies in Sepsis: A Deeper Dive

Sepsis demands timely, effective antimicrobial therapy, but does how we administer beta-lactam antibiotics matter? In this episode, we take a deeper dive into the growing evidence behind prolonged beta-lactam infusion strategies and explore why recent guidelines now recommend extended or continuous infusions for many patients with sepsis and septic shock. We unpack the pharmacokinetic and pharmacodynamic principles, review key clinical trials and meta-analyses demonstrating improved outcomes, and discuss the critical role of an appropriate loading dose. We also examine which patient populations may benefit the most, including those with augmented renal clearance or altered physiology and when therapeutic drug monitoring should be considered. Finally, we tackle the practical challenges of implementing prolonged infusions in clinical practice, from drug stability and IV compatibility to the unanswered questions surrounding antimicrobial resistance.

Ketamine During OAT Initiation: Can It Help in the Fentanyl Era?

Ketamine is best known for its roles in analgesia, sedation, and depression, but could it also help patients navigate the most challenging phase of opioid agonist therapy initiation in the fentanyl era? In this episode, we explore the emerging science behind ketamine as an adjunctive treatment for opioid withdrawal and OAT initiation, including its potential effects on NMDA receptors, opioid tolerance, and receptor signaling. We review the latest clinical evidence, from case reports of refractory withdrawal to early studies suggesting improved retention in treatment through rapid relief of depression and withdrawal distress. We'll also unpack the fascinating biology of beta-arrestin, receptor internalization, and whether ketamine may help improve opioid responsiveness by rebalancing some of the neurobiological changes associated with chronic fentanyl exposure. Join us as we separate promise from proof and discuss where ketamine may fit and where it may not in the future of addiction care.

Time Is Blood: Why Early TXA Saves Lives in Trauma

In this episode, we explore the race against time in trauma care and why every minute matters when treating life-threatening bleeding. Drawing on evidence from major clinical trials and meta-analyses, we examine how tranexamic acid (TXA) can dramatically improve survival when administered as early as possible after injury. You'll learn why the greatest benefits occur within the first hour, why effectiveness begins to decline after 90 minutes, and how even short delays can significantly reduce a patient's chance of survival. We also discuss emerging evidence suggesting that rapid treatment may be more important than where the treatment is delivered. Whether you're a healthcare professional, student, or simply interested in emergency medicine, this episode highlights how timely intervention can save lives in trauma, hemorrhagic shock, and traumatic brain injury.

Blood Pressure Management in Acute Intracerebral Hemorrhage

How low should you go when lowering blood pressure in acute intracerebral hemorrhage, and can treating too aggressively actually cause harm? In this episode, we explore the pathophysiology of ICH, including why spontaneous hemorrhage lacks a true ischemic penumbra and how perihematomal benign oligemia supports the safety of blood pressure reduction. We review the landmark INTERACT-2 and ATACH-II trials, along with the newer INTERACT-3 and INTERACT-4 studies, to uncover how the evidence has shaped modern practice and reinforced the lesson that lower is not always better. We discuss current guideline recommendations, including the shift toward a systolic blood pressure target of 130 to 150 mmHg and the importance of minimizing blood pressure variability. Finally, we compare commonly used agents such as nicardipine and clevidipine and revisit the longstanding controversy surrounding hydralazine and its purported effects on intracranial pressure and hematoma expansion.